Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
Please provide your email address to receive an email when new articles are posted on . Up-dosing sessions occurred weekly, followed by monthly maintenance dosing. Venoms included honeybee, yellow ...
With several anti-amyloid antibodies now proven to clear plaque from the human brain, researchers are turning their attention to fine-tuning immunotherapy for Alzheimer’s disease. At the 16th ...
The approval was based on data from the phase 3 TMB-302 trial that evaluated Trogarzo 800mg administered via IV push once every 2 weeks. The Food and Drug Administration (FDA) has approved Trogarzo ® ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
Ultomiris is administered intravenously by a healthcare professional, with infusion times varying from 24 to 90 minutes or more depending on the dose. The dosage of Ultomiris is determined by body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results